Hemant Surgical Industries Limited

BSE: HSIL543916ISIN INE0GYI01028

Healthcare
Medical Equipment & Supplies

Share price

₹608.10+10.75 (+1.80%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹679.00
52W low: ₹215.00
Off 52W high: -10.44%
1M return: +0.78%
3M return: +63.25%
6M return: +108.36%
1Y return: +109.69%
20D avg volume: 15,120
50 DMA: ₹526.23
200 DMA: ₹377.22

Key ratios Consolidated

Market cap: ₹884.03 Cr
Current price: ₹608.10
52W high / low: ₹679.00 / ₹215.00
Face value: ₹10.00
P/E: —
P/B: —
EPS (TTM): —
Book value / share: —
ROE: —
ROCE: 19.50%
Operating margin: —
Net margin: —
Debt / equity: —
Net debt: —
Interest cover: 6.94
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 86.7 days

Financials

Metric	FY26	FY25	FY24
Income statement
	231.81	106.64	—
	5.86	5.12	—
	237.67	111.76	—
	214.08	101.29	—
	187.91	94.26	—
	0.00	0.00	—
	10.09	9.34	—
	3.97	2.20	—
	1.54	1.43	—
	19.94	12.62	—
	23.59	10.47	—
	0.00	0.00	—
	23.59	10.47	—
	5.40	2.42	—
	18.19	8.04	—
	15.39	7.70	—
Key metrics
	29.10	14.10	—
	12.60%	13.20%	—
	7.80%	7.50%	—
	19.50%	14.60%	—
	117.40%	—	—
	126.20%	—	—
	-33.69	-28.73	—
	-1.76	1.10	—
	86.7	84.1	—
Balance sheet
	274.26	148.31	—
	192.42	88.80	—
	43.84	9.55	—
	67.35	20.38	—
	59.05	43.14	—
	13.21	8.09	—
	53.45	39.93	—
	71.31	38.98	—
	133.09	61.26	—
Cash flow
	-32.04	8.84	—
	-2.97	-30.28	—
	69.31	17.64	—
	1.65	37.57	—

Metric	FY26	FY25	FY24
Income statement
	230.99	106.53	105.61
	5.73	5.11	4.31
	236.71	111.64	109.92
	213.08	101.08	97.14
	187.39	94.06	80.16
	0.00	0.00	—
	9.97	9.33	7.60
	3.97	2.20	0.97
	1.52	1.42	1.03
	19.86	12.61	—
	23.63	10.55	12.78
	23.63	10.56	12.78
	5.40	2.42	2.98
	18.23	8.13	9.80
	15.42	7.79	—
Key metrics
	29.12	14.18	14.78
	12.60%	13.30%	14.00%
	7.90%	7.60%	9.30%
	19.60%	14.70%	—
	116.80%	0.90%	—
	124.20%	-17.00%	—
	-33.67	-28.76	—
	-1.76	1.10	—
	86.5	82.1	—
Balance sheet
	274.01	147.64	—
	192.02	88.00	—
	43.83	9.46	—
	67.25	20.31	—
	58.65	42.48	—
	13.20	8.09	—
	53.40	39.87	—
	71.21	38.81	—
	132.98	60.77	—
Cash flow
	-32.02	8.92	—
	-2.97	-30.28	—
	69.37	17.64	—
	1.65	37.68	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 52.82%

Holder	Type	Holding	Previous	Change
HANSKUMAR SHAMJI SHAH	Promoter	24.26%	—	—
KAUSHIK HANSKUMAR SHAH	Promoter	14.47%	—	—
HEMANT PRAFUL SHAH	Promoter	11.93%	—	—
SINGULARITY LARGE VALUE FUND III	Public	6.19%	—	—
SINGULARITY EQUITY FUND I	Public	6.19%	—	—
SINGULARITY LARGE VALUE FUND I	Public	3.44%	—	—
WEALTHWAVE CAPITAL TRUST-WEALTHWAVE CAPITAL FUND	Public	2.75%	—	—
MONA LAROIA	Public	2.42%	—	—
RENU DEVI HISARIA	Public	2.06%	—	—
SWATI POKHARNA	Public	1.53%	—	—
BIMLA BAJAJ .	Public	1.38%	—	—
SINGULARITY EQUITY FUND II	Public	1.38%	—	—
NARESH SARAAF	Public	1.27%	—	—
NAMAN HEMANT SHAH	Promoter Group	0.65%	—	—
LEENA HANSKUMAR SHAH	Promoter Group	0.60%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Poly Medicure Ltd	16,093	1,587.65	51.43	13.20%	+18.31% TTM	-12.49% TTM	-18.70%
MOLBIO DIAGNOSTICS LIMITED	15,901	1,379.80	—	—	—	—	—
Sahajanand Medical Technologies Limited	4,939	485.85	—	—	—	—	—
FISCHER MEDICAL VENTURES LIMITED	1,655	25.29	59.29	12.70%	+195.94% TTM	+371.52% TTM	-73.00%
Tarsons Products Limited	1,651	310.35	148.83	4.80%	+10.63% TTM	-59.68% TTM	+7.85%
Laxmi Dental Limited	1,036	188.30	31.98	11.50%	+13.07% TTM	+24.85% TTM	-40.71%
Hemant Surgical Industries Limited	884	608.10	—	19.50%	—	—	+109.69%
Fabtech Technologies Limited	591	133.05	16.61	11.60%	—	—	-44.16%
Prevest Denpro Limited	480	400.00	—	21.90%	—	—	-23.80%
Nureca Limited	288	301.65	60.46	3.40%	+33.66% TTM	+15.82% TTM	+17.10%
EARKART LIMITED S	161	117.00	32.59	12.10%	—	—	-48.46%
CHOKSI ASIA LIMITED S	120	210.00	23.08	18.40%	+21.40% TTM	+132.74% TTM	+97.28%
Shree Pacetronix Ltd	63	169.15	19.60	25.00%	+22.63% TTM	+208.57% TTM	-38.65%
Amkay Products Limited S	46	53.50	20.04	13.40%	—	—	+13.88%
KMS Medisurgi Limited S	44	132.80	177.07	4.80%	—	—	—
Royal Sense Limited	36	67.70	—	26.10%	—	—	-70.69%
GKB Ophthalmics Ltd.	31	62.00	5.67	9.60%	+29.95% TTM	+170.50% TTM	-9.48%
Centenial Surgical Suture Ltd. S	26	71.96	-17.99	2.60%	+6.70% TTM	+26.29% TTM	-33.37%
Transpact Enterprises Limited S	4	100.70	—	14.50%	—	—	-57.35%

Some figures use IPO-document inputs. Growth periods are shown per value; FY means annual.

Filings & corporate actions

Recent announcements

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 20267 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Scrutinizer Report and Voting result of AGM held on September 29, 202629 Sep 2026 · AGM/EGM / AGM
Proceeding of AGM held on Tuesday, September 29, 202629 Sep 2026 · AGM/EGM / AGM
Closure of Trading Window28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper publication regarding Notice of 37th Annual General Meeting and Remote E-voting information.5 Sep 2026 · Company Update / Newspaper Publication
The Company has sent letters to those shareholders whose email addresses are not registered.4 Sep 2026 · Company Update / General
Notice of AGM and Integrated Annual Report for F.Y. 25-264 Sep 2026 · Others / Reg. 34 (1) Annual Report
37th AGM of the Company is scheduled to be held on September 29, 2026 through VC/OAVM.4 Sep 2026 · AGM/EGM / AGM
Newspaper Advertisement for Notice of AGM to be held through Video Conferencing (VC)/ Other Audio Visual Means (OAVM).31 Aug 2026 · Company Update / Newspaper Publication
The Company has considered and decided to hold AGM of the Company on September 29, 2026 through VC/OAVM.29 Aug 2026 · Others / Outcome without intimation
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 202610 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In continuation to disclosure dated March 31, 2026, minor modification have been made in attached disclosure.9 Jun 2026 · Company Update / General
Please find enclosed Press Release being issued by the Company titled "Hemant Surgical Strengthens Healthcare Portfolio through Strategic Acquisition of Majority Stake in Lifesenz Cancer ....9 Jun 2026 · Company Update / Press Release / Media Release
With reference to intimation dated May 27, 2026, the Company has completed the acqusition of Lifesenz Cancer Labs Private Limited and has become subsidiary of the Company w.e.f. June 01, 2026.1 Jun 2026 · Company Update / Acquisition
Non-Applicability of Annual Secretarial Compliance Report for the Financial Year Ended March 31, 202630 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
The Company at its meeting held today i.e., May 27, 2026 has entered into Share Purchase Agreement (''SPA'') for acquisition of 66.66% equity shareholding of Lifesenz Cancer Labs Private ....27 May 2026 · Company Update / Acquisition
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Singularity Equity Fund I20 May 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Singularity Large Value Fund III20 May 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Allotment of 14,99,200 Equity Shares consequent to conversion of Convertible Warrants15 May 2026 · Company Update / Allotment of Equity Shares
The Board of Directors at its meeting held today has appointment M/s. K Sorathiya & Co, Practicing Cost Accountants as Cost Auditor of the Company for F.Y. 26-2715 May 2026 · Company Update / General
The Board of Directors at its Meeting held today has appointed M/s. A D M S and Company, Chartered Accountant as Internal Auditor of the Company for F.Y. 26-2715 May 2026 · Company Update / General
The Board of Directors at its Meeting held today has appointed M/s. NKM & Associates as Secretarial Auditor of the Company for F.Y. 26-2715 May 2026 · Company Update / General
Audited Financial Results of the Company for half and financial year ended March 31, 202615 May 2026 · Result / Financial Results
The Board of Directors at its meeting held today have approved Audited Financial Results of the Company for half and financial year ended March 31, 202615 May 2026 · Board Meeting / Outcome of Board Meeting
Hemant Surgical Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2026 ,inter alia, to consider and approve Audited Standalone ....9 May 2026 · Board Meeting / Board Meeting
Certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2026.7 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Company has executed C-ARM Development and Supply Agreement with GBT Korea Co, Ltd, Republic of Korea.2 Apr 2026 · Company Update / Memorandum of Understanding /Agreements
The Company has entered into Strategic Semi Knocked Down (SKD) Manufacturing Agreement with Sonomed Escalon, USA31 Mar 2026 · Company Update / General
Intimation of Closure of Trading Window27 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation of receipt of purchase order from Central Medical Services Society, Ministry of Health and Family Welfare (Government of India).19 Feb 2026 · Company Update / Award of Order / Receipt of Order
Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018.12 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Statement of Deviation or Variation for half year ended on September 30, 202512 Nov 2025 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Statement of Deviation or Variation for the half year ended on September 30, 2025.12 Nov 2025 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Unaudited financial results of the Company for the half year ended on September 30, 2025.12 Nov 2025 · Result / Financial Results
Outcome of Board Meeting held on Wednesday, November 12, 2025, pursuant to Regulations 30, 33 and other applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) ....12 Nov 2025 · Board Meeting / Outcome of Board Meeting
Hemant Surgical Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve unaudited financial ....5 Nov 2025 · Board Meeting / Board Meeting
Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2025.13 Oct 2025 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation regarding closure of trading window27 Sep 2025 · Insider Trading / SAST / Closure of Trading Window
Proceedings and Scrutinizer report of the 36th Annual General Meeting (''AGM'') of Hemant Surgical Industries Limited ("the Company") held on Tuesday, September 23, 2025.23 Sep 2025 · AGM/EGM / AGM
Proceedings and Voting Results of the 36th Annual General Meeting (''AGM'') of Hemant Surgical Industries Limited (''the Company'') held on Tuesday, September 23, 2025.23 Sep 2025 · AGM/EGM / AGM